Article
Enhanced detection of minimal residual disease by targeted sequencing of phased variants in circulating tumor DNA.
Nature biotechnology - 1 Dec 2021
Kurtz David M, Soo Joanne, Co Ting Keh Lyron, Alig Stefan, Chabon Jacob J, Sworder Brian J, Schultz Andre, Jin Michael C, Scherer Florian, Garofalo Andrea, Macaulay Charles W, Hamilton Emily G, Chen Binbin, Olsen Mari, Schroers-Martin Joseph G, Craig Alexander F M, Moding Everett J, Esfahani Mohammad S, Liu Chih Long, Dührsen Ulrich, Hüttmann Andreas, Casasnovas René-Olivier, Westin Jason R, Roschewski Mark, Wilson Wyndham H, Gaidano Gianluca, Rossi Davide, Diehn Maximilian, Alizadeh Ash A
Abstract excerpt
Circulating tumor-derived DNA (ctDNA) is an emerging biomarker for many cancers, but the limited sensitivity of current detection methods reduces its utility for diagnosing minimal residual disease. Here we describe phased variant enrichment and detection sequencing (PhasED-seq), a method that uses multiple somatic mutations in individual DNA fragments to improve the sensitivity of ctDNA detection. Leveraging...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.